NDC 68151-3971

Aggrenox

Aspirin And Dipyridamole

Aggrenox is a Oral Capsule, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Carilion Materials Management. The primary component is Aspirin; Dipyridamole.

Product ID68151-3971_b085f4e8-f461-454e-9aff-4f18d9888a8b
NDC68151-3971
Product TypeHuman Prescription Drug
Proprietary NameAggrenox
Generic NameAspirin And Dipyridamole
Dosage FormCapsule, Extended Release
Route of AdministrationORAL
Marketing Start Date1999-12-19
Marketing CategoryNDA / NDA
Application NumberNDA020884
Labeler NameCarilion Materials Management
Substance NameASPIRIN; DIPYRIDAMOLE
Active Ingredient Strength25 mg/1; mg/1
Pharm ClassesCyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC],Platelet Aggregation Inhibitor [EPC],Decreased Platelet Aggregation [PE],Decreased Platelet Aggregation [PE],Platelet Aggregation Inhibitor [EPC]
NDC Exclude FlagE
Listing Certified Through2018-12-31

Packaging

NDC 68151-3971-6

1 CAPSULE, EXTENDED RELEASE in 1 PACKAGE (68151-3971-6)
Marketing Start Date1999-12-19
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 68151-3971-6 [68151397106]

Aggrenox CAPSULE, EXTENDED RELEASE
Marketing CategoryNDA
Application NumberNDA020884
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date1999-12-19
Inactivation Date2020-01-31

Drug Details

Active Ingredients

IngredientStrength
ASPIRIN25 mg/1

OpenFDA Data

SPL SET ID:f07c8535-f9fb-4697-9b63-1ab22210efc9
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1362082
  • 259081
  • Pharm Class PE
  • Decreased Prostaglandin Production [PE]
  • Decreased Platelet Aggregation [PE]
  • PHarm Class EPC
  • Nonsteroidal Anti-inflammatory Drug [EPC]
  • Platelet Aggregation Inhibitor [EPC]
  • NUI Code
  • N0000008832
  • N0000008836
  • N0000175721
  • N0000000160
  • N0000175578
  • N0000175722
  • Pharmacological Class

    • Cyclooxygenase Inhibitors [MoA]
    • Decreased Prostaglandin Production [PE]
    • Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient]
    • Nonsteroidal Anti-inflammatory Drug [EPC]
    • Platelet Aggregation Inhibitor [EPC]
    • Decreased Platelet Aggregation [PE]
    • Decreased Platelet Aggregation [PE]
    • Platelet Aggregation Inhibitor [EPC]

    NDC Crossover Matching brand name "Aggrenox" or generic name "Aspirin And Dipyridamole"

    NDCBrand NameGeneric Name
    0597-0001Aggrenoxaspirin and dipyridamole
    21695-656Aggrenoxaspirin and dipyridamole
    68151-3971Aggrenoxaspirin and dipyridamole
    0093-3040Aspirin and DipyridamoleAspirin and Dipyridamole
    0093-3064Aspirin and DipyridamoleAspirin and Dipyridamole
    0115-1711aspirin and dipyridamoleaspirin and dipyridamole
    0781-2141aspirin and dipyridamoleaspirin and dipyridamole
    16714-964Aspirin and DipyridamoleAspirin and Dipyridamole
    43598-339Aspirin and DipyridamoleAspirin and Dipyridamole
    70436-092aspirin and dipyridamoleaspirin and dipyridamole

    Trademark Results [Aggrenox]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    AGGRENOX
    AGGRENOX
    75368731 2355730 Live/Registered
    BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    1997-10-06

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.